Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Trace Metal Concentrations in Specimens of Patients With Lymphoma
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Pretreatment Vitamin D Deficiency Associated With Outcomes in Hodgkin Lymphoma
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging Mass Cytometry Reveals Prognostic Immune Phenotypes in DLBCL
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
Durvalumab Adds No Benefit to Single-Agent Ibrutinib in FL, DLBCL
The combination warrants no further study in these patients.
FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Nurse Practitioner-Led Rapid Diagnosis Clinic May Reduce Time to Diagnosis in Lymphoma
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Autoimmune Conditions Associated With Primary Central Nervous System Lymphoma
Significant associations were found between primary central nervous system lymphoma and systemic lupus erythematosus, myasthenia gravis, and uveitis.
Inferior Response Following Early Relapse in Frontline Treatment for Aggressive B-Cell Lymphomas
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
BAFF-R-CAR-T to Overcome Resistance: Q&A With Dr Hong Qin
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Determining Prognosis for Patients With Diffuse Large B-Cell Lymphoma
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Long-Term Health Following the Lymphome Malin de Burkitt Chemotherapy Regimen
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Survival Disparities in Pediatric Patients With Lymphoma Based on Ethnicity
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
A Salvage Therapy Option for Follicular Lymphoma Makes Headway
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
Tailored Monitoring May Be Warranted in Patients With Diffuse Large B-Cell Lymphoma
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Implant-Associated Cancers: A Look Beyond BIA-ALCL
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Advanced-Stage Classic Hodgkin Lymphoma Survival Outcomes Throughout the Years
Improved rates of 3-year overall survival were seen in patients who were younger and who were diagnosed more recently.
Improving the Clinical Diagnosis and Classification of Gray Zone Lymphomas
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
Long-Term Venous Thromboembolism Risk Following Blood or Marrow Transplantation for Non-Hodgkin Lymphoma
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
Incidence of GI Adverse Events Associated With CAR-T Therapy for Lymphoma or Leukemia Is Low
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Consensus Opinion Addresses Concerns About Clinical Application of CAR-T
A global task force makes recommendations for safe and appropriate use.
No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
Use of Interim PET/CT to Stratify Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Patients with positive interim PET/CT demonstrated poorer overall and progression-free survival compared with patients with negative interim PET/CT.
M7-FLIPI Score Not Predictive of Outcomes in Chemo-Free Regimens for Follicular Lymphoma
Researchers did not find a significant difference in survival outcomes for high- and low-risk patients with follicular lymphoma receiving immunotherapy.
Newly Identified Mutation May Result in Venetoclax Resistance in Follicular Lymphoma
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
Genetic Overlap Between Autoimmune Disease and NHL Not Supported by Genome-Wide Association Study
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
Efficacy of 19-28z CAR-T in DLBCL Unclear: Phase 1 Study Readout
The investigational treatment was associated with a high rate of neurotoxicity.
Rituximab Upfront Therapy and Late Relapse Risk in Diffuse Large B-Cell Lymphoma
Fewer patients who experienced late relapse received upfront rituximab compared with patients who experienced early relapse.
Carbapenem Reduces Tumor Burden in Patients With Cutaneous T-Cell Lymphomas and Bacterial Infection
Antibiotic treatment with carbapenem for S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
Frontline Treatment Strategies and Therapeutic Options for Mantle Cell Lymphoma
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Rituximab With or Without Lenalidomide in First-Line Treatment of Follicular Lymphoma
Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.
Follow-Up S0816 Trial Results: PET-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.
Concurrent Indolent Lymphomas in Diffuse Large B-Cell Lymphoma Do Not Worsen Clinical Outcomes
Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.
Relapsed Follicular Lymphoma: Stem Cell Transplantation in the Era of Targeted Therapies
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Subtype of CXCR4 Mutation Correlated With Inferior Response to Ibrutinib in Waldenström Macroglobulinemia
Nonsense mutations in CXCR4, but not frameshift mutations, were associated with poor response compared with no mutation in CXCR4.
Current and Prospective Treatment Strategies for Follicular Lymphoma
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Diagnostic Delay in Diffuse Large B-Cell Lymphoma Linked to Poorer Outcomes for Patients With Worse Disease
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
HIV-Induced Expression of PD-L1 on Regulatory B Cells May Promote AIDS-Related NHL
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Factors Associated With Long-Term Fatigue in Non-Hodgkin Lymphoma Survivors
Severe fatigue was more common in NHL survivors compared with the general population.
Pregnant Patients With Lymphoma Can Be Safely and Effectively Treated
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Late Relapse Rates After Immunochemotherapy Treatment for Diffuse Large B-Cell Lymphoma
Patients who achieved event-free survival at 24 months following diagnosis were evaluated for late relapses.
Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia
The model stratified patients into 3 risk groups based on median time to disease progression.
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
